Caredx Stock Price, News & Analysis

CareDx, Inc. (CDNA) has announced its participation in the upcoming ASHI conference, featuring eight scientific abstracts related to AlloSeq Tx17 and AlloSeq HCT. The conference will take place from September 27-30, 2021, in Orlando, FL, showcasing innovations in transplant care. CEO Reg Seeto expressed pride in advancing transplant solutions, emphasizing the transformative role of AlloSeq HCT. Additionally, CareDx will host a lunch symposium discussing future innovations across the transplant journey.

CareDx Appoints Art Torres to Board of Directors

CareDx, Inc. (Nasdaq: CDNA) announced the appointment of Art Torres to its Board of Directors. Torres, a former California state senator and advocate for organ transplantation, brings extensive expertise in regenerative medicine and health equity. He is currently involved with several organizations, including the California Institute for Regenerative Medicine and One Legacy. His addition to the board is seen as a move to strengthen CareDx's commitment to improving support for transplant patients across diverse communities.

CareDx, a precision medicine company, announces its participation in two upcoming healthcare conferences. The first is the 2021 Wells Fargo Healthcare Conference on September 9, 2021, at 3:20 p.m. Eastern Time, with a live webcast available on the company's investor relations site. The second event is the H.C. Wainwright 23rd Annual Global Investment Conference, where CareDx will present on September 13, 2021, at 7:00 a.m. Eastern Time. CareDx specializes in solutions for transplant patients, offering services and products that enhance the pre- and post-transplant experience.

CareDx launches AlloSeq cfDNA Research Service and showcases leadership at ESOT 2021.

On August 26, 2021, CareDx, Inc. (Nasdaq: CDNA) announced its presence at the European Society of Organ Transplantation (ESOT) conference with six abstracts and an upcoming symposium. The AlloSeq cfDNA service detects donor-derived cfDNA in less than 24 hours and aims to expand research internationally from its Stockholm lab. The ESOT symposium on August 29 will highlight advanced strategies for allograft surveillance, featuring experts in the field.

CareDx, Inc. (Nasdaq: CDNA) reported second-quarter 2021 financial results with total revenue of $74.2 million, a 77% increase year-over-year. Testing services revenue reached $64.9 million, up from $36.3 million in Q2 2020. Notably, the company has generated approximately 37,400 AlloSure and AlloMap patient results this quarter. Despite a net loss of $1.9 million, an improvement from $6.6 million in the previous year, the company reported a non-GAAP net income of $5.9 million. CareDx raised its 2021 revenue guidance to a range of $280-$290 million.

CareDx, Inc. (NASDAQ: CDNA) has announced the enrollment of the first patient in the ACROBAT study, which investigates the potential of the AlloHeme testing tool in predicting relapse for patients undergoing allogeneic hematopoietic cell transplants. This multicenter study aims to evaluate the effectiveness of AlloHeme, which uses next-generation sequencing to monitor donor and recipient cell levels, enhancing patient surveillance post-transplant. With around 10,000 such transplants annually in the U.S., the outcome of this study could significantly impact patient care and surveillance in this area.

CareDx, Inc. (Nasdaq: CDNA) announced it will report its financial results for Q2 2021 after market close on July 29, 2021. A conference call hosted by company management will follow at 1:30 p.m. PT (4:30 p.m. ET). Investors can participate by calling 877-705-6003 domestically or 201-493-6725 internationally, using Conference ID: 13721182. Live webcasts will be available on CareDx's investor relations website.

CareDx specializes in precision medicine solutions for transplant patients, emphasizing genomics-based information throughout the pre- and post-transplant journey.

CareDx has launched the AlloCare app on the Android Play Store, complementing its availability on iOS, aimed at assisting organ transplant patients in managing their health pre-and-post-transplant. This user-friendly app offers features such as medication management, lab appointment scheduling, and biometric tracking, effectively doubling the total addressable user base. The app's design was heavily influenced by input from transplant recipients and patient organizations, ensuring it meets the specific needs of users, whether they are awaiting a transplant or years post-operation.

CareDx, Inc. (Nasdaq: CDNA) has announced the appointment of Dr. Hannah Valantine to its Board of Directors. Dr. Valantine, a Professor at Stanford and former Chief Scientific Officer at NIH, is recognized for her leadership in transplant medicine and diversity initiatives. She has collaborated with CareDx on important publications related to transplant biomarkers. Her extensive clinical background and innovative approach will enhance CareDx's Scientific Advisory Committee and support the company's mission to improve patient care in the transplant community.